{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:04:01Z","timestamp":1783191841835,"version":"3.54.6"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01024-y","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T16:26:52Z","timestamp":1754670412000},"page":"805-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sustained eGFR improvement after dapagliflozin in a patient with antiretroviral therapy-related chronic kidney disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Hirotaka","family":"Arae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Moromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tokumine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1636-7889","authenticated-orcid":false,"given":"Kentaro","family":"Kohagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"6","key":"1024_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semnephrol.2008.08.005","volume":"28","author":"CM Wyatt","year":"2008","unstructured":"Wyatt CM, Klotman PE, D\u2019Agati VD. HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol. 2008;28(6):513\u201322.","journal-title":"Semin Nephrol"},{"issue":"1","key":"1024_CR2","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","volume":"3","author":"A Mocroft","year":"2016","unstructured":"Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23-32.","journal-title":"Lancet HIV"},{"issue":"15","key":"1024_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"1024_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"4","key":"1024_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10157-013-0853-1","volume":"18","author":"N Yanagisawa","year":"2014","unstructured":"Yanagisawa N, Muramatsu T, Yamamoto Y, Tsuchiya K, Nitta K, Ajisawa A, et al. Classification of human immunodeficiency virus-infected patients with chronic kidney disease using a combination of proteinuria and estimated glomerular filtration rate. Clin Exp Nephrol. 2014;18(4):600\u20135.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1024_CR6","doi-asserted-by":"publisher","first-page":"zqac065","DOI":"10.1093\/function\/zqac065","volume":"4","author":"A Pearson","year":"2023","unstructured":"Pearson A, Haenni D, Bouitbir J, Hunt M, Payne BAI, Sachdeva A, et al. Integration of high-throughput imaging and multiparametric metabolic profiling reveals a mitochondrial mechanism of tenofovir toxicity. Function (Oxf). 2023;4(1):zqac065.","journal-title":"Function (Oxf)"},{"issue":"13","key":"1024_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1097\/QAD.0000000000000347","volume":"28","author":"T Nishijima","year":"2014","unstructured":"Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903\u201310.","journal-title":"AIDS"},{"issue":"2","key":"1024_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/QAD.0000000000001667","volume":"32","author":"T Nishijima","year":"2018","unstructured":"Nishijima T, Mutoh Y, Kawasaki Y, Tomonari K, Kikuchi Y, Gatanaga H, et al. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. AIDS. 2018;32(2):179\u201388.","journal-title":"AIDS"},{"issue":"4","key":"1024_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/infdis\/jiaa125","volume":"222","author":"B Surial","year":"2020","unstructured":"Surial B, Ledergerber B, Calmy A, Cavassini M, G\u00fcnthard HF, Kovari H, et al. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. J Infect Dis. 2020;222(4):637\u201345.","journal-title":"J Infect Dis"},{"issue":"1","key":"1024_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12981-021-00380-w","volume":"18","author":"T Ueaphongsukkit","year":"2021","unstructured":"Ueaphongsukkit T, Gatechompol S, Avihingsanon A, Surintrspanont J, Iampenkhae K, Avihingsanon Y, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review. AIDS Res Ther. 2021;18(1):53.","journal-title":"AIDS Res Ther"},{"issue":"9","key":"1024_CR11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41440-020-0426-0","volume":"43","author":"K Kohagura","year":"2020","unstructured":"Kohagura K, Yamasaki H, Takano H, Ohya Y, Seino Y. Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes. Hypertens Res. 2020;43(9):876\u201383.","journal-title":"Hypertens Res"},{"issue":"11","key":"1024_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1024_CR13","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"J O\u2019Neill","year":"2015","unstructured":"O\u2019Neill J, Fasching A, Pihl L, Patinha D, Franz\u00e9n S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309(3):F227\u201334.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"1024_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2215\/CJN.11480821","volume":"17","author":"DLS Suijk","year":"2022","unstructured":"Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17(5):663\u201371.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1024_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/nep.13645","volume":"25","author":"DL Suijk","year":"2020","unstructured":"Suijk DL, Smits MM, Muskiet MH, Tonneijck L, Kramer MH, Joles JA, et al. Plasma uric acid and renal haemodynamics in type 2 diabetes patients. Nephrology (Carlton). 2020;25(4):290\u20137.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"1024_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798\u2013810.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1024_CR17","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29(7):1867\u201376.","journal-title":"Nat Med"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01024-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01024-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01024-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:12:56Z","timestamp":1762845176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01024-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01024-y","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kohagura received personal fees for lecture from AstraZeneca, Ono Pharma, Boehringer IngelheimTanabe Mitsubishi, and Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the participant included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}